RecruitingNCT06673043
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
Anifrolumab Real-world Treatment Outcomes in Polish Patients With Systemic Lupus Erythematosus (SLE). Multicenter, Non-interventional Study
Sponsor
AstraZeneca
Enrollment
100 participants
Start Date
Feb 28, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Adult (aged ≥18 years old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland.
- Patients willing to participate in the study and signed Informed Consent Form (ICF).
Exclusion Criteria2
- Those who participated in anifrolumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first anifrolumab infusion through NDP.
- Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAnifrolumab
Anifrolumab 300 mg concentrate for solution for infusion
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06673043
Related Trials
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
NCT0733024519 locations
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT072011299 locations
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT0701598393 locations
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
NCT074242616 locations
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT0743849627 locations